Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study
Authors:
- Rochelle BagatellRBRochelle Bagatell
- Kieran McHughKMKieran McHugh
- Arlene NaranjoANArlene Naranjo
- Collin Van RynCRCollin Van Ryn
- Chaim KirbyCKChaim Kirby
- Penelope BrockPBPenelope Brock
- Karen A. LyonsKLKaren A. Lyons
- Lisa J. StatesLSLisa J. States
- Yesenia RojasYRYesenia Rojas
- Alexandra MillerAMAlexandra Miller
- Sam L. VolchenboumSVSam L. Volchenboum
- Thorsten SimonTSThorsten Simon
- 1 March 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (7) , 740-746
Abstract
Purpose: The International Neuroblastoma Response Criteria (INRC) require serial measurements of primary tumors in three dimensions, whereas the Response Evaluation Criteria in Solid Tumors (RECIST) require measurement in one dimension. This study was conducted to identify the preferred method of primary tumor response assessment for use in revised INRC. Patients and Methods: Patients younger than 20 years with high-risk neuroblastoma were eligible if they were diagnosed between 2000 and 2012 and if three primary tumor measurements (antero-posterior, width, cranio-caudal) were recorded at least twice before resection. Responses were defined as ≥ 30% reduction in longest dimension as per RECIST, ≥ 50% reduction in volume as per INRC, or ≥ 65% reduction in volume. Results: Three-year event-free survival for all patients (N = 229) was 44% and overall survival was 58%. The sensitivity of both volume response measures (ability to detect responses in patients who survived) exceeded the sensitivity of the single dimension measure, but the specificity of all response measures (ability to identify lack of response in patients who later died) was low. In multivariable analyses, none of the response measures studied was predictive of outcome, and none was predictive of the extent of resection. Conclusion: None of the methods of primary tumor response assessment was predictive of outcome. Measurement of three dimensions followed by calculation of resultant volume is more complex than measurement of a single dimension. Primary tumor response in children with high-risk neuroblastoma should therefore be evaluated in accordance with RECIST criteria, using the single longest dimension.Keywords
This publication has 28 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- Results of a Quality Assurance Review of External Beam Radiation Therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: A SIOPEN StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high‐risk neuroblastomaCancer, 2012
- Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in RhabdomyosarcomaJournal of Clinical Oncology, 2010
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trialThe Lancet Oncology, 2008
- Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas1Neuro-Oncology, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958